Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 11/20 | 0.75 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.51 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21708428 | 0.98 | EPHX1 (0.72) | EPHX1POLBEPHX2GNAI3GNAO1 | |
| SCHEMBL26553729 | 0.88 | EPHX1 (0.57) | EPHX1POLBEPHX2GNAI3GNAO1 | |
| SCHEMBL14097638 | 0.88 | EPHX1 (0.57) | EPHX1POLBEPHX2GNAI3GNAO1 | |
| SCHEMBL14097633 | 0.88 | EPHX1 (0.57) | EPHX1POLBEPHX2GNAI3GNAO1 | |
| Trifluoroacetic Acid SCHEMBL28169254 | 0.88 | EPHX1 (0.58) | EPHX1POLBEPHX2GNAI3GNAO1 | |
| SCHEMBL5142091 | 0.86 | EPHX1 (1.00) | EPHX1POLBEPHX2GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL5743237 | 0.86 | EPHX1 (0.55) | EPHX1POLBEPHX2GNAI3GNAO1 | |
| SCHEMBL28171895 | 0.84 | EPHX1 (0.95) | EPHX1POLBEPHX2GNAI3GNAO1 | |
| SCHEMBL10155582 | 0.84 | EPHX2 (0.56) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL965099 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714499-A2 | POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2026-03-25 | — | — | EP | disclosed |
| US-20250230129-A1 | POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF | JIANGSU NHWA PHARMACEUTICAL CO., LTD (CN) | 2025-07-17 | — | — | US | disclosed |
| EP-4497754-A1 | POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2025-01-29 | — | — | EP | disclosed |
| CN-118891270-A | Polyamide compound, preparation method and medical application thereof | 江苏恩华药业股份有限公司 | 2024-11-01 | — | — | CN | disclosed |
| EP-3873600-B9 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2024-02-14 | — | — | EP | disclosed |
| US-20230331683-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2023-10-19 | — | — | US | disclosed |
| WO-2023179659-A1 | POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF | 江苏恩华药业股份有限公司 | 2023-09-28 | — | — | WO | disclosed |
| EP-3873600-B1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2023-09-20 | — | — | EP | disclosed |
| US-20230174487-A1 | PHENYLPROPIONAMIDE COMPOUND AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2023-06-08 | — | — | US | disclosed |
| US-20230174487-A1 | PHENYLPROPIONAMIDE COMPOUND AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2023-06-08 | — | — | US | disclosed |
| US-20160311807-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| CN-102464631-B | Piperazine substituted 1,3-2-substituted carbamide compounds and the substituted amides compound of piperazine and its production and use | 中国科学院上海药物研究所 | 2016-08-10 | — | — | CN | disclosed |
| WO-2015089479-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| CN-102464631-A | Piperazine substituted 1,3-disubstitued urea compounds and piperazine substituted amide compounds, preparation method, and use thereof | SHANGHAI INST MATERIA MEDICA | 2012-05-23 | — | — | CN | disclosed |
| WO-2008023159-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | WO | disclosed |
| EP-1337512-B1 | (4-ACYLAMINOPIPERIDIN-1-YL) ACETAMIDES AS NEUROKININ ANTAGONISTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-06-13 | — | — | EP | disclosed |
| US-6664253-B2 | N-phenethyl-2-aryl-2-(4-(oxy-or amino-carbonylamino)piperidin-1-yl)acetamide derivatives | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-12-16 | — | — | US | disclosed |
| EP-1337512-A1 | (4-ACYLAMINOPIPERIDIN-1-YL) ACETAMIDES AS NEUROKININ ANTAGONISTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-08-27 | — | — | EP | disclosed |
| US-20020115666-A1 | Neurokinin antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-22 | — | — | US | disclosed |
| WO-2002032866-A1 | (4-ACYLAMINOPIPERIDIN-1-YL) ACETAMIDES AS NEUROKININ ANTAGONISTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230129-A1 | POLYAMIDE COMPOUNDS, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF | ADCYAP1R1, PAICS, AGPS | EPHX1 2964/4885POLB 299/4885EPHX2 443/4885 |
| US-20230331683-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | SPNS2, SPCS2, SMN1; SMN2 | EPHX1 3679/4885POLB 2637/4885EPHX2 1688/4885 |
| US-20020115666-A1 | Neurokinin antagonists | TACR2, TACR1, NPSR1 | EPHX1 2806/4885POLB 4863/4885EPHX2 3126/4885 |
| US-20160311807-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | EPHX1 1227/4885POLB 2303/4885EPHX2 2632/4885 |
| US-20230174487-A1 | PHENYLPROPIONAMIDE COMPOUND AND USE THEREOF | PAH, TRPV1, TRPA1 | EPHX1 267/4885POLB 3687/4885EPHX2 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.